Skip to main content
KRSA
NASDAQ Life Sciences

Korsana Resubmits Cayman Islands Redomestication After Failed Vote, Proposes Classified Board and Exclusive Forum

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Negative
Importance info
8
Price
$30.72
Mkt Cap
$1.399B
52W Low
$7.186
52W High
$59.36
52W Position info
327% above low
Off High info
48% below high
Rel. Volume info
3.7× avg
Market data snapshot near publication time

KRSA has more than doubled off its 52-week low of $7.186 on elevated volume (3.7× avg).

Summary

Korsana Biosciences is resubmitting a proposal to redomesticate from Massachusetts to the Cayman Islands after it failed in August. The new Cayman articles would create a classified board and limit shareholder litigation to Cayman Islands courts.


Key Events · Corporate Governance and Compliance · KRSA

  • Redomestication Proposal Resubmitted

    The board is resubmitting the proposal to move the company's domicile from Massachusetts to the Cayman Islands after it failed at the August 26, 2026 annual meeting, where it received 61.8% of votes cast but only 44.8% of outstanding shares.

  • Classified Board Introduced

    The proposed Cayman articles would divide the board into three classes with staggered three-year terms, replacing the current annual election of all directors and making it harder for shareholders to replace the board.

  • Exclusive Forum in Cayman Islands

    The Cayman articles designate Cayman Islands courts as the exclusive forum for shareholder derivative actions and internal affairs claims, limiting shareholders' ability to sue in U.S. courts.

  • Series B Preferred Protective Provisions

    The Cayman Series B Preferred Shares would require majority holder consent for fundamental transactions, board size increases, and retention or replacement of auditors, compensation consultants, or corporate counsel.


Analysis · KRSA · Life Sciences

The board is asking shareholders to approve moving the company's legal domicile from Massachusetts to the Cayman Islands after the same proposal failed at the August 26, 2026 annual meeting. The new Cayman articles would introduce a classified board with staggered three-year terms, making it harder for shareholders to replace directors, and would designate Cayman Islands courts as the exclusive forum for shareholder lawsuits. These changes reduce shareholder litigation rights and entrench management, which is why the board is resubmitting the proposal despite the prior failure.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, KRSA was trading at $30.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $7.19 to $59.36. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

KRSA - Latest Insights

KRSA
Nov 05, 2026, 8:00 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $30.56
Real-time Price: $37.56 info
Change: +$7.00 (+23%) info
Market Cap: $1.711B info
KRSA
Nov 05, 2026, 7:05 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $30.56
Real-time Price: $37.56 info
Change: +$7.00 (+23%) info
Market Cap: $1.711B info
KRSA
Nov 05, 2026, 7:00 AM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $30.56
Real-time Price: $37.56 info
Change: +$7.00 (+23%) info
Market Cap: $1.711B info